In the last trading session, 1.27 million Vaxcyte Inc (NASDAQ:PCVX) shares changed hands as the company’s beta touched 1.29. With the company’s per share price at $34.77 changed hands at $1.87 or 5.68% during last session, the market valuation stood at $4.48B. PCVX’s last price was a discount, traded about -248.17% off its 52-week high of $121.06. The share price had its 52-week low at $27.66, which suggests the last value was 20.45% up since then. When we look at Vaxcyte Inc’s average trading volume, we note the 10-day average is 1.69 million shares, with the 3-month average coming to 1.99 million.
Analysts gave the Vaxcyte Inc (PCVX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended PCVX as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Vaxcyte Inc’s EPS for the current quarter is expected to be -0.98.
Vaxcyte Inc (NASDAQ:PCVX) trade information
Instantly PCVX was in green as seen at the end of in last trading. With action 11.23%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -57.53%, with the 5-day performance at 11.23% in the green. However, in the 30-day time frame, Vaxcyte Inc (NASDAQ:PCVX) is -49.94% down. Looking at the short shares, we see there were 12.34 million shares sold at short interest cover period of 3.65 days.
The consensus price target for the stock as assigned by Wall Street analysts is 140.5, meaning bulls need an upside of 75.25% from its current market value. According to analyst projections, PCVX’s forecast low is 135 with 146 as the target high. To hit the forecast high, the stock’s price needs a -319.9% plunge from its current level, while the stock would need to soar -288.27% for it to hit the projected low.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -29.88%. The 2025 estimates are for Vaxcyte Inc earnings to decrease by -20.61%, but the outlook for the next 5-year period is at -6.42% per year.
PCVX Dividends
Vaxcyte Inc is expected to release its next quarterly earnings report on 2025-Feb-24.
Vaxcyte Inc (NASDAQ:PCVX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.50% of Vaxcyte Inc shares while 111.86% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 112.42%. There are 111.86% institutions holding the Vaxcyte Inc stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 13.788% of the shares, roughly 16.17 million PCVX shares worth $1.22 billion.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 8.477% or 9.94 million shares worth $750.56 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 3.74 shares estimated at $130.06 million under it, the former controlled 2.90% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 2.53% of the shares, roughly 3.26 shares worth around $113.52 million.
